Given the clinical significance of high-risk thrombophilia (homozygous factor V Leiden or prothrombin G20210A mutations, natural anticoagulant deficiencies, and antiphospholipid antibody syndrome [APS]), we aimed to determine its prevalence and the clinical and laboratory factors associated with its diagnosis across diverse patient populations. This evidence concerns the gene F2 and Rare hereditary thrombophilia.